Apellis Pharmaceuticals APLS 深 沪
交易中 08-14 10:02:17 美东时间
26.60
+0.020
+0.08%
华盛通- 最 高27.05
- 今 开26.17
- 成交量 23.16万股
- 最 低 26.055
- 昨 收 26.58
- 总市值 33.52亿
- 52周最高 41.94
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 16.10
- 委 比 14.94%
- 总股本 1.26亿
- 历史最高 94.75
- 量 比 2.33
- 振 幅 3.74%
- 历史最低 11.45
- 每 手 1
- 风险率 6.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What to Expect from Kymera Therapeutics's Earnings
Kymera Therapeutics (NASDAQ:KYMR) is gearing up to announce its quarterly earni...
08-08 23:01
美股大行评级 | 花旗、小摩分别上调苹果目标价；瑞穗上调Robinhood目标价从99美元升至120美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从46美元升至52美元；BTIG：维持Strategy"买入"评级，目标价从620美元升至700美元
08-04 09:30
Raymond James Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $50
Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price target from $52 to $50.
08-01 21:20
Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Nasdaq Composite gaining around 150 points on...
07-31 23:00
Apellis Pharmaceuticals Q2 EPS $(0.33) Beats $(0.48) Estimate, Sales $178.494M Miss $187.790M Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 10 percent decrease over losses of $(0.30) per share
07-31 18:56
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
美股大行评级 | 潜在涨幅36%！花旗上调Coinbase目标价升至505美元；摩根大通维持迪士尼"超配"评级，目标价升至138美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从41美元升至46美元；杰富瑞：维持Kiniksa Pharmaceuticals"买入"评级，目标价从45美元升至54美元
07-30 09:36
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Apellis Pharmaceuticals announced the FDA approval of EMPAVELI (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years and older. The approval is based on the VALIANT study, which demonstrated significant reduction in proteinuria (68%), stabilization of kidney function, and substantial clearance of C3 deposits. EMPAVELI is the first treatment fo...
07-28 23:19
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
Apellis Pharmaceuticals announced it will host a conference call and webcast on July 31, 2025, at 8:30 a.m. ET, to discuss its second quarter 2025 financial results. Registration for the call and access to a live audio webcast with slides are available through the company's website. A replay will be available for 90 days. Apellis is a global biopharmaceutical company developing therapies for challenging diseases, with two approved medicines targe...
07-24 11:00
